Apalutamide with primary radiation therapy for treating high-risk, localised or locally advanced prostate cancer

Apalutamide with androgen deprivation therapy (ADT), is in clinical development for patients with high-risk localised or locally advanced prostate cancer who are receiving primary radiation therapy. Prostate cancer is a cancer of the prostate gland (a small organ in a man’s pelvis) and is the most common cancer in men in the UK. The symptoms may vary depending on the stage of cancer but can include pain, tiredness, and problems emptying the bladder and the bowels. Prostate cancer growth and spread depends on the hormone testosterone. Locally advanced prostate cancer is cancer that has started to break out of the prostate, or has spread to the area just outside the prostate.